US Stock Market Move | BEIGENE (ONC.US) rises more than 3% in pre-market trading, Lenvima monoclonal antibody approved for new indication in the United States.

On Tuesday, BEIGENE (ONC.US) saw its US stock price rise over 3% in pre-market trading to $253.98. On the news front, on March 4th, BEIGENE announced that the US FDA had approved the combination of tislelizumab (anti-PD-1 antibody) with platinum-based chemotherapy for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) in adult patients with PD-L1 expression (1).